Cytheris’ CYT107 quadruples CD4 cell count in HIV treatment non-responders
Paris – French immune modulation specialist Cytheris SA has announced positive results of its recombinant Interleukin-7 drug CYT107 in a Phase IIa study. According to the company, CYT107 was able to reconstitute CD4 T-cells in chronically HIV-1 infected patients whose CD4 T-cell counts remained low despite treatment with anti-retroviral-therapies (HAART). In addition to providing further evidence of the ability of IL-7 to stimulate the expansion of CD4 and CD8 T-cells in peripheral blood, the results demonstrate the importance of IL-7 in stimulating T-cell repopulation of the lymphoid tissue layer in the mucous membrane of the gastro-intestinal tract – an effect that had been already demonstrated in SIV infected ,monkeys. In 7 out of 12 patients, who received a weekly CYT107 injection over three months, the CD4 count quadrupled (from 272 and 554 cell/mm3 at baseline to 679 and 986 cells/mm3 at week 12). CYT107, which was well-tolerated in all patients, also decreased PD-1 frequency, a marker of T cell exhaustion, in both CD4 and CD8 T-cells. This confirms the ability of IL-7 treatment to drive T-cells to the gut mucosa and facilitate their expansion. Numerous experimental and clinical studies confirm that T-cell reconstitution in the gut is critical for restoring control over the HIV virus.